COVID-19 and the Heart
- 8 May 2020
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 126 (10), 1443-1455
- https://doi.org/10.1161/circresaha.120.317055
Abstract
Infection with the novel coronavirus, SARS-CoV-2, produces a clinical syndrome known as COVID-19. When severe, COVID-19 is a systemic illness characterized by hyperinflammation, cytokine storm and elevations of cardiac injury biomarkers. Here we review what is known about the pathophysiology of COVID-19, its cardiovascular manifestations, and emerging therapeutic prospects. In this rapidly moving field, this review was comprehensive as of April 3, 2020.Keywords
This publication has 93 references indexed in Scilit:
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARSEuropean Journal of Clinical Investigation, 2009
- Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy SpecimensCirculation, 2007
- Multiple organ infection and the pathogenesis of SARSThe Journal of Experimental Medicine, 2005
- Natural regulatory T cells in infectious diseaseNature Immunology, 2005
- ACE2: from vasopeptidase to SARS virus receptorTrends in Pharmacological Sciences, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002
- Two ACEs and a heartNature, 2002